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Pediatric inflammatory bowel disease (pIBD) is a chronic heterogeneous disorder. This study looks at the 
burden of common and rare coding mutations within 41 genes comprising the NOD signaling pathway 
in pIBD patients. 136 pIBD and 106 control samples underwent whole-exome sequencing. We compared 
the burden of common, rare and private mutation between these two groups using the SKAT-O 
test. An independent replication cohort of 33 cases and 111 controls was used to validate significant 
findings. We observed variation in 40 of 41 genes comprising the NOD signaling pathway. Four genes 
were significantly associated with disease in the discovery cohort (BIRC2 p = 0.004, NFKB1 p =  0.005, 
NOD2 p = 0.029 and SUGT1 p = 0.047). Statistical significance was replicated for BIRC2 (p = 0.041) and 
NOD2 (p = 0.045) in an independent validation cohort. A gene based test on the combined discovery 
and replication cohort confirmed association for BIRC2 (p = 0.030). We successfully applied burden of 
mutation testing that jointly assesses common and rare variants, identifying two previously implicated 
genes (NFKB1 and NOD2) and confirmed a possible role in disease risk in a previously unreported gene 
(BIRC2). The identification of this novel gene provides a wider role for the inhibitor of apoptosis gene 
family in IBD pathogenesis.
Inflammatory bowel disease (IBD) is an umbrella term for a group of complex and multifactorial illnesses: 
Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU)1. The etiology 
of IBD is multi-genic and environmentally triggered, but generally accepted to occur as a result of an inappropri-
ate immune response to the normal gut flora in genetically predisposed individuals2.
Since the discovery of NOD2 in 2001 as the first susceptibility gene for IBD3, over 200 loci have been associ-
ated with IBD risk in humans through genome wide association studies (GWAS)4,5. GWAS have provided sub-
stantial insight into the understanding of the biology of complex diseases by providing robust and replicated 
evidence for autophagy2, immune response2 and bacterial recognition2 patterns. However, an intrinsic limitation 
of these studies is their focus on common variation, typically those with a minor allele frequency (MAF) ≥ 5% in 
the general population. The combined contribution of these common mutations to IBD heritability only account 
for 13.6% of CD and 8.2% of UC, respectively6. It is hypothesized that low frequency (MAF of 0.05–5%) and rare 
(MAF ≤ 0.05%) variation may contribute significantly towards some fraction of the missing heritability of IBD6–8.
Recent technological advances in DNA sequencing have made it possible to sequence large tracts of the genome 
in a cost-effective manner. This has enabled large-scale studies of the impact of rare variants on complex diseases9. 
Whole-exome (WES) and whole genome sequencing (WGS) have improved the understanding of genetic cause 
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of diseases by revealing variants not captured by GWAS10. It is estimated that ~85% of disease-causing mutations 
reside within the coding regions of the genome11. Therefore, targeting these expressed regions of the genome 
represents the most cost-effective means to uncover causal disease genes12.
Pediatric onset IBD (pIBD) presents with unique phenotypic characteristics and pronounced severity com-
pared to adult-onset disease13. PIBD is more often characterized by extensive intestinal involvement, rapid early 
progression and a high rate of resistance to conventional therapy1. Moreover, early-onset IBD has a stronger 
familial component than adult disease1. These combined features indicate a stronger genetic component to pIBD 
compared to IBD diagnosed in adulthood.
GWAS are powered to assess common genetic variation in large patient cohorts that are often composed of 
adults, in order to amass sizeable patient groups. Large cohorts of patients with disease onset in childhood are less 
easily ascertained and also likely enriched for rare or private variation of large effect14. Approximately 300 genes 
Figure 1. Proteins acting within the NOD signaling pathway. The recognistion of NOD1 and NOD2 of the 
bacterial peptidoglycan (PGN) promotes the formation of the multi-protein complex named inflammasome. 
The complex recruits the kinase receptor interacting protein 2 (RIP2), which is ubiquitinated by the ubiquitin 
ligases XIAP, BIRC2 and BIRC3 proteins. The polyubiquitinated RIP2 recruits the kinase TAK1 and TAK 
binding protein 1 (TAB1), TAB2 and TAB3 which leads to the activation of the MAPK kinases, p38 and c-Jun 
N-terminal kinase (JNK) through the activation of mitogen-activated protein kinase kinase (MKK). RIP2 
polyubiquitinated also interacts with the IKK complex (IKKα , IKKβ and NEMO). The IKK complex mediates 
the phosphorylation of the IKKβ subunit of IKK by TAK1 and results in the phosphorylation and degradation 
of the NF-κ B inhibitor (Iκ Bα ) which results in the cytoplasmic release and translocation of NF-κ B dimers p65 
and p50 in the nucleus to activate of the expression of the NF-κ B proinflammatory genes.
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Figure 2. NOD2 gene and protein. NOD2 is a gene composed of 12 exons (black rectangles). The NOD2 
protein consists of two N-terminal caspase activation recruitment (CARD) domains, a central nucleotide-
binding oligomerization (NBD) domain and a terminal sequence rich in leucine (LRR). The CARD domains 
interact with RIP2 protein to activate the immune response in the gut and the leucine-rich domain recognizes 
the bacterial peptidoglycan. Mutations within the NBD have been shown to increase the inflammatory cascade. 
The 31 mutations observed by interrogating exome data from 136 pIBD and 106 controls are depicted using 
arrows and the corresponding protein change noted. Known IBD biomarkers are in red.
Figure 3. BIRC2 gene and protein. BIRC2 is a gene composed of 9 exons (black rectangles). BIRC2 encodes 
an inhibitor of apoptosis protein, which contributes to innate immune responses by acting as inhibitor of cell 
death. All the members of the inhibitor of apoptosis (IAP) gene family share three tandem specific motifs: BIR 
belonging to the zinc-finger domain that mediates protein-protein interaction, a CARD domain is involved 
in CARD-CARD mediated interaction; and a C-terminal RING domain conferring an E3-ubiquitin ligase 
activity. The RING domain of BIRC2, BIRC3, and XIAP is required for the ubiquitin activity of the IAPs. Studies 
have reported that the CARD domain in BIRC2 and BIRC3 act as an inhibitor of the ubiquitin ligase activity. 
Mutations within the BIR1 domain in BIRC2 alters molecular interaction with TNF receptor associated factor 1 
(TRAF1) and TRAF2. The six mutations found by interrogating exome data from 136 pIBD and 106 controls are 
depicted using arrows and the corresponding protein change shown.
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have been prioritized within the 200 loci determined through adult studies and only less than half have been 
replicated in a small number of pediatric studies15,16.
To date, 51 genes have been associated with monogenic disease manifesting in an early onset IBD-like pheno-
type17,18. Homozygous mutations in the interleukin 10 receptor (IL10) gene and its associated receptor alpha and 
beta subunits (IL10RA and IL10RB) have been associated with children presenting very-early-onset IBD (VEO, 
age of onset < 6 years)19,20. The discovery of the disease causal mutations helped to personalize treatments induc-
ing a sustained remission in the patients19,20. The investigation of a child with intractable IBD using whole-exome 
analysis by Worthey et al.21 found a hemizygous mutation in the gene X-linked inhibitor of apoptosis (XIAP). 
The same mutation was confirmed in the asymptomatic mother. Based on these findings, this patient underwent 
hematopoietic stem cell progenitor transplantation with a resolution of symptoms and sustained remission fol-
lowing this targeted treatment approach21.
XIAP belongs to the in inhibitor of apoptosis protein (IAP) family (comprising XIAP, BIRC2 and BIRC3) that 
plays a role in regulation of the innate immune response through ubiquitin ligase activity, TNF survival, inflam-
matory and death signaling pathways22,23. IAP proteins mediate the downstream signaling of pattern-recognition 
receptors such as NOD1 and NOD2 after response to bacterial pathogens24.
The NOD signaling pathway, Fig. 1, is involved in gram-negative and gram-positive peptidoglycan recog-
nition. NOD1 and NOD2 proteins are highly conserved cytoplasmatic receptors that sense microbial effectors. 
Activation of NOD receptors leads to downstream activation of multiple molecules including mitogen-activated 
protein kinases (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κ B)25.
In this study, we hypothesize that rare and private genetic variation across genes involved in the NOD sign-
aling pathway may contribute to childhood onset IBD. We interrogate WES data to extract all genetic variation 
across the frequency spectrum in a pIBD cohort and evaluate the joint effect of rare and common variants with a 
gene-based statistical test (SKAT-O26). We further validate our findings in an independent cohort.
Results
PCA procedure removed 10 cases and 20 controls reducing the final number of cases to 136 and controls to 106 
within the discovery cohort (Supplementary Figure 1). The analysis revealed no outliers in the replication cohort. 
(Supplementary Figures 2 and 3).
Mutations were identified in either cases and/or controls in all but one gene (CCL5) from the NOD signaling 
pathway in the discovery cohort (ncases = 136 and ncontrols = 106). A total of 250 variants (Supplementary Table 2) 
that occurred in at least one individual (either case or control) across 41 genes were called in order to extract 
and create the VCF file for all 242 individuals. We observed 67 novel variants, 94 rare variants with a MAF 
1000 genome project (1 KG) < 1%, 41 low frequency mutations (1% ≤ MAF1 KG ≥ 5%) and 48 common mutations 
(MAF1 KG > 5%). The majority of these variants would not have been detected or interrogated using array tech-
nology or traditional association studies.
Variants within the NOD2 gene. Across the 126 pIBD cases and 85 controls within the discovery cohort, 
we observed 31 mutations over 12 exons of the NOD2 gene. Of these, 26 had a MAF < 0.05 across the cohort 
(Table 1). Eight mutations were identified in or proximal to the caspase recruitment (CARD) domain, 16 in 
the nucleotide-binding oligomerization (NBD) domain and seven in the leucine-rich (LRR) domain (Fig. 2). In 
addition to the known IBD biomarkers, Arg702Trp, Gly908Arg and Leu1007fsinsC3,27, we observed two novel 
variants, 20 rare (MAF1 KG < 0.01), two low frequency (0.01 ≤ MAF1 KG ≤ 0.05) and four common mutations 
(MAF1 KG > 0.05) (Table 1). Ten of the 26 mutations were annotated as deleterious by SIFT and 13 are described 
in HGMD as pathogenic28. Twenty six (out of 31) mutations observed would not have been assessed in any GWAS 
due to their rarity.
Gene based burden of mutation testing in the discovery cohort. The gene-based test for assessing 
the combined association of novel, rare and common mutation with disease status showed significant evidence 
for association with four genes across the discovery cohort (BIRC2, NFKB1, NOD2, and SUGT1 see Table 2). 
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Table 1.  List of 31 NOD2 variants observed across the discovery cohort. ns , non-synonymous; sn, 
synonymous; fi, Wframeshift insertion, fd, frameshift deletion; sp, splicing; nfi, non-frameshift insertion; 
nfd, non-frameshift deletion, sp, splicing. CARD, caspase recruitment domain; NBD, Nucleotide-binding 
oligomerization domain; LRR, leucine-rich domain. B, benign; C, Conservative; D, deleterious; MC, moderately 
Conservative; MR, moderately Radical; NR, not reported; P, possibly damaging; R, radical; T, tolerated.
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NFKB1 (p = 0.005) and NOD2 (p = 0.029) are known IBD associated genes. SUGT1 is a previously unreported 
gene but has borderline significance only (p = 0.047). Combined variation in BIRC2 is more significantly asso-
ciated (p = 0.004) with IBD in our discovery cohort than any other genes. This gene has not been previously 
implicated by association studies.
Replication of the gene based burden of mutation test in the validation cohort. We aim to con-
duct a replication analysis of the four gene identified as significant in the discovery phase using a replication 
Gene Chromosome bp position (hg19)
Total number 
of samples 
(136 cases; 
106 controls)
Fraction of individuals 
who carry rare variants 
under the MAF thresholds 
(MAF < 0.05)*
Number of 
all variants 
defined in the 
group file
Number of 
variant defined 
as rare (MAF 
< 0.05)*
P-value 
unadjusted
BIRC2 11 102220918–102248410 242 0.07851 6 6 0.004
NFKB1 4 103488139–103537672 242 0.11983 10 9 0.005
NOD2 16 50733392–50763778 242 0.21488 31 25 0.029
SUGT1 13 53231709–53261936 242 0.33058 6 5 0.047
MAPK11 22 50703796–50706381 242 0.07024 7 5 0.061
CARD6 5 40841561–40853404 242 0.0909 10 8 0.074
BIRC3 11 102195774–102201850 242 0.05371 6 6 0.075
TAB2 6 149699333–149730846 242 0.07024 6 6 0.117
IKBKB 8 42128942–42188489 242 0.06198 6 6 0.249
ERBB2IP 5 65307924–65372200 242 0.17355 13 9 0.292
CASP8 2 202122956–202149864 242 0.0909 8 6 0.319
MAPK12 22 50691870–50699668 242 0.19835 16 13 0.35
TAB3 X 30849697–30877801 242 0.02066 5 4 0.362
CHUK 10 101964267–101980355 242 0.02892 6 4 0.38
TNFAIP3 6 138196066–138202378 242 0.06198 7 7 0.653
NOD1 7 30487954–30496518 242 0.08264 17 13 0.657
TRIP6 7 100465128–100469223 242 0.07438 11 9 0.783
TAB1 22 39795831–39832516 242 0.02479 7 6 0.795
MAPK13 6 36098410–36107131 242 0.02892 9 8 0.799
RIPK2 8 90770315–90802611 242 0.07438 5 4 0.803
CARD9 9 139258615–139266519 242 0.16942 12 10 0.866
Table 2.  Joint variant test (SKAT-O) result for the 41 genes within the NOD signaling pathway in which 
variations was found across the entire discovery cohort. Only genes in which at least five variants were 
entered into the model are shown. *These variants received different weights in the SKAT-O joint test. Genes are 
ordered by p-value.
Gene Chromosome
bp position 
(hg19) Dataset
Total 
number 
of 
samples
Fraction of 
individuals who carry 
rare variants under 
the MAF thresholds 
(MAF < 0.05)*
Number of 
all variants 
defined  
in the  
group file
Number 
of variant 
defined as 
rare (MAF 
< 0.05)*
P-value 
unadjusted
BIRC2 11 102219940–102249151
Replication cohort (33 
cases; 111 controls) 144 0.11806 3 2 0.041
Combined replication and 
validation cohort (169 
cases; 217 controls)
386 0.04663 1 1 0. 030
NOD2 16 50733859–50763778
Replication cohort (33 
cases; 111 controls) 144 0.11111 8 3 0.045
Combined replication and 
validation cohort (169 
cases; 217 controls)
386 0.041451 4 2 0.011
NFKB1 4 103505961–103514658
Replication cohort (33 
cases; 111 controls) 144 0.02777 2 1 0.223
Combined replication and 
validation cohort (169 
cases; 217 controls)
386 0.05699 2 1 0.017
Table 3.  SKAT-O test result for the four significant genes within the NOD signaling pathway in which 
variations was found across the replication cohort only and across the combined discovery and replication 
cohort. *These variants received different weights in the SKAT-O joint test. Genes are ordered by p-value.
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cohort (ncases = 33; ncontrols = 111). A total of 13 variants were identified across the regions sequenced in the NFKB1, 
BIRC2, NOD2 gene. No variant was observed in SUGT1 in the replication cohort and therefore SKAT-O test was 
not conducted on this gene. SKAT-O test showed independent statistical association for BIRC2 (p = 0.041) and 
NOD2 (p = 0.045) but was not powered to detect significant association for NFKB1 (p = 0.223), Table 3. The gene 
based test on the combined discovery and replication cohort (n cases  =  169 and n controls  =  217) showed sta-
tistical association for NOD2 (p = 0.011), NFKB1 (p = 0.017) and BIRC2 (p =  0.030), Table 3.
Discussion
Since 2005 next generation sequencing (NGS) has proven to be an effective technology for the study of rare and 
low frequency mutations within disease-associated genes29. More than 100 types of Mendelian disorders have 
been studied using WES with a diagnostic rate of success of 25–30%30. This success represents a substantially 
higher rate than that afforded by classical clinical genetic testing such as karyotyping (< 5%) or array compar-
ative genomic hybridization (~15–20%)30 The combination of traditional genetic testing and WES/WGS tech-
nology has rapidly accelerated the discovery of new disease-associated genes underlying Mendelian traits: from 
an average of 166 per year between 200530 and 2009 to 236 per year between 2010 and 201430, with the numbers 
increasing every year. WES/WGS has made gene discovery for all phenotypes feasible and cost effective30. The 
rapid growth and success of the next generation sequencing technologies in Mendelian traits has brought a great 
interest in their application to complex traits. WES and WGS have enable diagnosis and alternative treatment in 
patients with monogenic IBD18.
In our study we applied WES and the SKAT-O statistical test on a discovery cohort of 242 individuals. We 
conducted the analysis with no assumption with regard to IBD diagnosis (CD, UC or IBDU) because in half of the 
families recruited in the study we observed mixed diagnoses reflecting the substantial genetic overlap between 
IBD subtypes. Although our data were derived from whole exome sequencing, we did not conduct SKAT-O on all 
gene across the exome due to our modest sample size. Instead, we targeted our analysis to all 41 genes across the 
NOD signaling pathway removing the requirement of an exome-wide significance threshold31. We chose to select 
the most significantly associated genes and to replicate their significance in an independent replication cohort. A 
limitation of the replication analysis was the use of data gleaned from different sources. Although an established 
method to take into account such differences is not yet available32,33, we minimized bias by analyzing only variants 
that occurred in the regions common to all capture kits.
Despite a modest cohort size, we detected significant association in four genes and replicated significant asso-
ciation for two genes (NOD2 and BIRC2).
NOD2 is the earliest gene implicated in IBD pathogenesis and the most strongly associated in association stud-
ies with IBD34. Polymorphisms within NOD2 are known to increase the risk of developing CD.35 NOD2 patient 
carriers of one of the three allelic biomarker variants have an increased risk of developing CD: heterozygous carri-
ers have a 2–4-fold increased risk of CD, while homozygous or compound heterozygous carriers have a 20–40-fold 
increased risk34.The association for NOD2 was solely driven by the three known biomarkers (Table S3).
BIRC2 (Fig. 3) belongs to a gene family (XIAP, BIRC2 (also known as cIAP1) and BIRC3 (also known as 
cIAP2)) encoding three conserved proteins characterized by the presence of 1-3 baculovirus IAP repeat (BIR) 
motifs36. XIAP is located on the X chromosome while BIRC2 and BIRC3 are both located on chromosome 11. 
Several studies have demonstrated the importance of these genes in regulating the expression of proinflammatory 
cytokines, such as TNFα , through NF-kB and MAPK pathways primarily through their ubiquitin-ligase activity. 
XIAP, BIRC2 and BIRC3 are key players in regulating the NOD1 and NOD2 signaling pathway by directly pro-
moting RIPK2 ubiquitylation and they facilitate activation of NF-kB pathway to promote cell survival37. Cellular 
studies on BIRC2, BIRC3 and XIAP deficient macrophages were defective for MAPKs and NF-kB activation23,38. 
This defect in the NOD signaling was also further observed in vivo in BIRC2, BIRC3 and XIAP knockout murine 
IBD models38. BIRC2 and BIRC3 are inhibitors of the Fas signaling cascade in human intestinal cell line23. The 
expression profile of BIRC3 was further investigated in 14 UC patients indicating an overexpression in colonic 
specimens during disease flares39. Additional studies on the interleukin (IL)-11 expression suggested a possible 
protective role of IAP, indicating that an over-expression of the IAP proteins could promote healing of the gut40. 
It is therefore feasible that mutations within these genes might impact gut healing and contribute to flares in IBD. 
Six variants within BIRC2 were observed in the discovery cohort across 15 cases and 4 controls. Three of these 
were novel (p.112_113del, p.S154A and p.G517E), two were rare (p.K516E and p.S318S) and one was low fre-
quency (p.A506V,). Across the 15 cases (four with CD, four with IBDU and seven with UC), four were diagnosed 
aged < 6 years, seven had a positive family history for IBD and nine were diagnosed with a second autoimmune 
condition other than IBD. While our observed enrichment of variation within BIRC2 directly implicates this 
gene in pediatric IBD, further functional analyses are necessary for a comprehensive understanding of the role 
of individual variants in this protein and their wider impact on the signaling pathway. While mutations in XIAP 
are known to cause up to 4% of male early onset IBD, it is has been postulated that BIRC2 and BIRC3 might con-
tribute to IBD pathogenesis by regulating the inflammatory cascade through their ubiquitin-ligase activity, our 
findings are the first to directly implicate this genes in pIBD41.
Novel drugs that mimic the natural endogenous inhibitor of the IAP (the mitochondria-derived activator of 
caspases, SMAC) have been proposed to suppress the pro-inflammatory immune response in the gastro-intestinal 
tract for patient with moderate to severe disease activity42. It is possible that patients harboring BIRC2 mutations 
may benefit from new treatments targeting IAP expression and function. Further studies are required to assess the 
role of targeted therapy in the clinical management of these patients.
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Conclusions
A gene based burden of mutation test for association using sequencing data on a small cohort have supported 
the involvement of NFKB1 and NOD2 in the pathogenesis of IBD and have confirmed a role for BIRC2 in the 
pathogenesis of disease. This is the first study highlighting the role of BIRC2 in IBD through targeted exome 
sequencing.
Methods
Ethics statement. This study was approved by the Southampton and South West Hampshire Research 
Ethics Committee (REC) (09/H0504/125) and University Hospital Southampton Foundation Trust Research & 
Development (RHM CHI0497).
This study was approved by the Institutional Review Board (IRB) at The Children’s Mercy Hospital (IRB 
#15050179).
All methods were conducted in accordance with the relevant guidelines and regulations. Written informed 
consent was obtained for every participant.
Cases and samples. For the discovery cohort, patients were recruited through pediatric gastroenterology 
clinics at University Hospital Southampton (UHS), a regional center providing tertiary pediatric gastroenterology 
and endoscopy service for the Wessex region in Southern England. Written informed consent was provided by an 
attending parent or legal guardian for all pediatric recruits. All children aged < 18 at the point of diagnosis were 
eligible for recruitment to the study. The mean age of the cohort was 10.97 years (min 1–max 17 years). Diagnosis 
was established using the Porto criteria. Clinical data were recorded for each patient including family history of 
IBD and any history of autoimmune disease. We accessed control samples through our local database of germline 
exome sequence data for 126 unrelated patients with no inflammatory-related disease.
We used an independent replication cohort derived from the Children’s Mercy Kansas City IBD cohort and 
the Critical Assessment of Genome Interpretation (CAGI, 2013)43 dataset to validate significant results from the 
discovery cohort. The Children’s Mercy Kansas City cohort consists of 43 whole-exome individuals of which 
13 are independent IBD patients and 1 control; the CAGI dataset is composed of 66 whole-exomes datasets (in 
VCF format) of which 20 are unrelated adult CD patients and 8 are unrelated healthy controls. We merged 102 
additional whole-genome control samples of British ethnicity from the 1 KG phase 3 dataset44 resulting in the 
retention of 33 unrelated cases and 111 independent controls for subsequent analysis in the validation cohort.
Discovery cohort DNA extraction. Genomic DNA for each of the Southampton patients undergoing 
exome sequencing was extracted from saliva or peripheral venous blood samples collected in EDTA using the 
salting out method. DNA concentration was estimated using the Qubit 2.0 Fluorometer and α 260:280 ratio calcu-
lated using a nanodrop spectrophomter. The average DNA yield obtained was 150 μ g/ml and approximately 20 ug 
of each patient DNA was extracted for next generation sequencing.
Whole-exome sequencing data generation and analysis. For the Southampton discovery and 
Children’s Mercy Kansas City cohort, whole-exome capture was performed using Agilent SureSelect Human 
all Exon 51 Mb (versions 4 and 5) capture kits and TruSeq Expanded Exome and Nextera Expanded Exome 
capture kits. Capture technology is characterized by rapid progress, including new content and improved probe 
design, and we applied the optimal capture chemistry available at the time of sample sequencing. All samples were 
sequenced on the Illumina HiSeq 2000 and HiSeq 2500 platforms. As previously described45, fastQ raw data gen-
erated from Illumina paired-end sequencing protocol were aligned against the human genome reference 19 using 
Novoalign (2.08.02). SAMtools mpileup tool (samtools/0.1.19) to call SNPs and short indels. Variants called with 
a read depth < 4 were excluded. The Phred software reads DNA sequencing trace files, calls bases, and assigns 
a quality value to each called base and is powered to discriminate between correct and incorrect base-calls. To 
minimize the false positive rate for the called bases, only variants called with high confidence (Phred score > 20) 
were retained for further analysis (99% base call accuracy). ANNOVAR (annovar/2013Feb21) was then applied 
for variant annotation. Genetic variants were annotated as “novel” if they were not previously reported in the 
dbSNP137 databases, 1000 Genomes Project (1 KG) and the Exome Variant Server (EVS) of European Americans 
of the NHLI-ESP project with 6500 exomes, or in the Southampton database of reference exomes. Resultant var-
iant call files for each individual were subjected to further in-house quality control tests to detect DNA sample 
contamination and ensure sex concordance by assessing autosomal and X chromosome heterozygosity. Variant 
sharing between all pairs of individuals was assessed to confirm that subjects were not related. Sample provenance 
was confirmed by application of a validated SNP tracking panel developed specifically for exome data46.
For the CAGI subgroup of the replication cohort, whole-exome sequencing was performed using the TruSeq 
capture kit and sequenced on Illumina platforms. Alignment against the human genome (hg19) was conducted 
with BWA. PICARD was used to remove duplicate reads and GATK for genotype calling. The VQSR method 
was used to identify true polymorphisms in the samples rather than those due to sequencing, alignment, or data 
processing artefacts43.
Gene selection. Genes involved in the NOD receptor pathway were extracted by interrogating the KEGG 
Pathway database47. The pathway (KEGG ID: hsa04621) is composed of 56 genes, of which 41 are intrinsic to 
NOD signaling. Gene names were cross-referenced with the HUGO webserver to confirm the approved gene 
symbol (Supplementary Table 1). All good quality (Depth ≥ 4 and Phred ≥ 20) variants within these genes were 
extracted using local scripts and retained for analyses. SKAT-O statistical test was then performed on the 41 genes 
directly involved in the NOD1 and NOD2 signaling cascade.
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Principle component analysis. Whole-exome sequencing data were available for 146 independent chil-
dren diagnosed with IBD within the discovery cohort. Demographic data for the IBD cohort are shown in Table 4.
In order to minimize bias for association analysis, we conducted a principle component analysis (PCA) using 
the SNPRelate48 package on the discovery and validation cohort to exclude non-Caucasian samples. PCA was 
conducted on the whole discovery dataset merged with the 1,092 subjects from the 1,000 genome phase 1 data-
set (20101123) in order to discriminate ethnic clusters. PCA was applied to 1363 samples with 305,950 biallelic 
SNPs. The same PCA procedure was conducted on the validation cohort using a combined set of CAGI and 
1,000 genome phase 1 data (209,029 biallelic SNPs across 1158 samples) and on the combined Kansas and 1,000 
genome phase 1 data (224, 786 biallelic SNP across 1134 samples) to discriminate ethnic clusters.
Variant calling and quality control. Next generation sequencing pipelines typically identify genomic 
locations at which any given sample differs from the human genome reference sequence on a case-by-case basis. 
After compiling the list of all variants identified in all cases and controls it was necessary to positively re-call the 
genotypic state (for the full set of all variants from all samples) in order to distinguish allelic genotypic status from 
missing data for each individual. The resultant genotypes were used for further analysis. Variants were excluded 
using vcftools if they deviated significantly from Hardy-Weinberg equilibrium status (p < 0.001) in the control 
group. Samples with a genotype missing call rate > 95% were also excluded. VCF files containing genotypic infor-
mation for all cases and controls were merged and annotated.
To detect association between genetic variant and disease status, a gene-based test (the sequence kernel asso-
ciation optimal unified test26, SKAT-O) was performed using the EPACTS software package49 in the discovery 
cohort. SKAT-O test was further conducted on the replication cohort to validate significant results from the 
discovery cohort.
Burden of mutation testing in the discovery cohort. SKAT-O statistical test was applied to further 
investigate the joint effect of rare and low frequency variants. Specifically, SKAT-O encompasses both a burden 
test and a SKAT test to offer a powerful means of conducting association analyses on combined rare and common 
variation as single variant tests are often underpowered due to the large sample size needed to detect a significant 
association.
To conduct the test, a group file with mutations of interests (synonymous, non-synonymous, splicing, 
frameshifts and non-frameshifts, stop gain and stop loss) was created for each of the 41 genes. SKAT-O was 
executed with the small sample adjustment, by using a MAF threshold of 0.05 to define rare variations within the 
sample size and using default weights26.
Burden of mutation testing in the validation cohort. As the validation cohort comprises of 
whole-exome and whole-genome subjects, only variants falling within the consensus target region were consid-
ered. By limiting variants assessed to only those found in the genomic regions captured by both technologies, 
we limited the potential for bias when using data from two different capture technologies. Variant sites across 
the four genes requiring replication were used to generate a subset of the VCF file for each dataset. Ultimately, 
VCF files for all individuals were merged and annotated. SKAT-O testing was conducted using the same settings 
applied in the discovery cohort.
SKAT-O testing was further conducted using the same approach on the combined discovery and replication 
cohorts (ncases = 169 and ncontrols = 217).
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